The first evidence indicated that a 4-week treatment with sitagliptin increased circulating EPC number (CD34+ and KDR+ cells) in a non-randomised study conducted in a small group of patients with type 2 diabetes [9]. This evidence concerns the gene KDR and type 2 diabetes mellitus.